newsfilter
← Latest News
GlobeNewswire·

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update

  • NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) will release its first quarter 2026 financial results before the market opens on Monday, May 18, 2026.
  • The financial results will be issued via press release available at https://ir.nrxpharma.com/.
  • The Company will host a conference call at 8:00am ET on May 18, 2026.
  • A live webcast of the call will be accessible at https://ir.nrxpharma.com/events.
  • Conference call telephone access is available domestically at 1-800-717-1738 or internationally at +1-646-307-1865.
  • NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing NMDA platform therapeutics for central nervous system disorders including suicidal depression, chronic pain, & PTSD.
  • The Company is developing NRX-100 (preservative-free intravenous ketamine) & NRX-101 (oral D-cycloserine/lurasidone).
  • NRX-100 has received Fast Track Designation for treating suicidal ideation in depression, including bipolar depression.
  • NRX-101 has received Breakthrough Therapy Designation for treating suicidal bipolar depression.
  • NRx has filed an Abbreviated New Drug Application (ANDA) & initiated a New Drug Application filing for NRX-100.
  • Brian Korb of astr partners serves as the contact for further information regarding the announcement.